Nuclear Medicine Radioisotopes Forecast Report – Designed for Decision Makers and Product Teams
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Nuclear Medicine Radioisotopes Market In 2029?
In recent times, the nuclear medicine radioisotopes market has been experiencing a significant expansion. This market, which was valued at $8.21 billion in 2024, is projected to reach $8.94 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.9%. Factors such as the detection of radioactivity, the advent of nuclear medicine, its therapeutic applications, clinical investigations, and increasing patient demand have contributed to the growth witnessed during the historic period.
What Growth Rate Is Forecasted for the Nuclear Medicine Radioisotopes Market by 2029?
The market size for nuclear medicine radioisotopes is anticipated to witness solid expansion over the upcoming years, with projections reaching $12.4 billion by 2029, showcasing a compound annual growth rate (CAGR) of 8.5%. The projected growth during the forecasted period is a result of factors such as the rise in healthcare spending, enhancement of healthcare facilities, heightened consciousness regarding environmental sustainability, educational drives and awareness programs, and the boom in medical tourism. Key trends expected in the forecast period feature the creation of novel radioisotopes, innovations in production and supply chain, breakthroughs in microfluidics and lab-on-a-chip technology, the use of artificial intelligence in the development of radiopharmaceuticals, and progress in nanotechnology.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp
Which Key Companies Are Shaping the Future of the Nuclear Medicine Radioisotopes Market?
Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacıbaşı-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation
Which Factors Are Driving Demand in the Nuclear Medicine Radioisotopes Industry?
The nuclear medicine radioisotope market is expected to see significant growth due to the increasing incidents of cardiovascular diseases. These diseases, which affect the heart and blood vessels, are becoming more common due to inactive lifestyles, unhealthy eating habits, rising obesity figures, and an aging demographic. Nuclear medicine radioisotopes play a crucial role in the diagnosis, evaluation and management of these diseases, providing valuable data about cardiac function, circulation, and tissue vitality, all of which are necessary for accurate identification and effective treatment strategies. As an example, the UK’s British Heart Foundation data from September 2024 revealed that around 7.6 million people suffer from heart and circulatory diseases in the country. This includes around 4 million men and 3.6 million women. These diseases account for approximately 27% of all UK deaths, leading to over 170,000 deaths annually, or about 480 each day, which equates to one death every three minutes. As a result, the escalating occurrences of cardiovascular diseases are fuelling the expansion of the nuclear medicine radioisotope market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=16132&type=smp
How Is the Nuclear Medicine Radioisotopes Market Segmented by Several Divisions?
The nuclear medicine radioisotopes market covered in this report is segmented –
1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types
2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications
3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users
Subsegments:
1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)
2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging
3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)
4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging
5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging
6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment
7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment
8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo)
9) By Alpharadin (Radium-223 Alpha Emitters): Alpharadin For Bone Metastasis Treatment
10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)
What are the Emerging Market Trends Driving the Growth of the Nuclear Medicine Radioisotopes Industry?
Leading companies in the nuclear medicine radioisotopes market are channeling their resources towards the development of novel products like the compact low-energy cyclotron, aiming to enhance the production and supply of radioisotopes. This will in turn ensure that diagnostic and therapeutic procedures are more efficient and readily accessible. Essentially, a compact, low-energy cyclotron is a mini particle accelerator designed to manufacture radioisotopes for use in nuclear medicine’s diagnostic imaging and treatment regimens. For example, IBA, a radiopharmaceutical production solutions provider based in Belgium, rolled out Cyclone Key in January 2022 – a new accelerator that improves accessibility to diagnostic interventions and facilitates the in-house generation of radiopharmaceuticals. This groundbreaking solution boasts unique features such as a svelte yet powerful design, full automation, the ability to produce multiple isotopes, easy installation and operation, water-cooling facilities, self-shielding, and exemplary performance, rendering it both multi-faceted and dependable.
Access The Full Report Here:
Which Regions Are Driving Growth in the Nuclear Medicine Radioisotopes Market?
North America was the largest region in the nuclear medicine radioisotopes market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16132
This Report Delivers Insight On:
1. How big is the nuclear medicine radioisotopes market, and how is it changing globally?
2. Who are the major companies in the nuclear medicine radioisotopes market, and how are they performing?
3. What are the key opportunities and risks in the nuclear medicine radioisotopes market right now?
4. Which products or customer segments are growing the most in the nuclear medicine radioisotopes market?
5. What factors are helping or slowing down the growth of the nuclear medicine radioisotopes market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
